Genocea Biosciences Inc. (GNCA) Issues Earnings Results
Genocea Biosciences Inc. (NASDAQ:GNCA) issued its quarterly earnings data on Thursday. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 0.45% during mid-day trading on Wednesday, hitting $4.44. 251,277 shares of the stock were exchanged. The company’s 50-day moving average is $5.35 and its 200-day moving average is $4.73. Genocea Biosciences has a 1-year low of $2.56 and a 1-year high of $8.20. The firm’s market cap is $125.80 million.
Several equities research analysts have recently weighed in on the stock. FBR & Co reissued a “buy” rating and issued a $17.00 target price on shares of Genocea Biosciences in a research report on Wednesday. Zacks Investment Research downgraded shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Genocea Biosciences in a research report on Thursday, September 29th. Finally, Piper Jaffray Cos. lowered their price objective on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, September 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Genocea Biosciences currently has an average rating of “Buy” and a consensus price target of $16.96.
Several institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Genocea Biosciences by 0.5% in the second quarter. FMR LLC now owns 4,244,037 shares of the company’s stock worth $17,401,000 after buying an additional 21,149 shares in the last quarter. Franklin Resources Inc. boosted its stake in Genocea Biosciences by 4.8% in the second quarter. Franklin Resources Inc. now owns 3,025,300 shares of the company’s stock valued at $12,404,000 after buying an additional 138,700 shares during the last quarter. Vanguard Group Inc. boosted its stake in Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock valued at $2,691,000 after buying an additional 57,062 shares during the last quarter. AXA boosted its stake in Genocea Biosciences by 1.4% in the second quarter. AXA now owns 595,157 shares of the company’s stock valued at $2,440,000 after buying an additional 8,183 shares during the last quarter. Finally, Paloma Partners Management Co bought a new stake in Genocea Biosciences during the second quarter valued at $334,000. Institutional investors own 56.49% of the company’s stock.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.